A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...

Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could generate monster gains next year as a rebound could be in the cards. Novo ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...

Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...